MedTrace Logo

Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to Antiretrovirals (ARVs)

NCT01103596 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 94

Last updated 2011-12-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate, in patients in at least the second protease inhibitor (PI) line, the virological failures under Kaletra® and their consequences on protease and reverse transcriptase genotypes

Conditions

  • HIV Infection

Sponsors & Collaborators

  • Readitwell

    collaborator UNKNOWN

  • Lincoln Medical and Mental Health Center

    collaborator OTHER

  • Abbott

    lead INDUSTRY

Principal Investigators

  • Isabelle Cohen Codar, PharmD · Abbott France

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01103596 on ClinicalTrials.gov